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Abstract
Bacterial vaginosis is the most prevalent cause of abnormal vaginal discharge
in women of childbearing age. It can have a major impact on quality of life and
psychological wellbeing if frequently recurrent and strongly symptomatic. The
use of molecular techniques to study the vaginal microbiome is increasing our
understanding of the dynamic changes in flora that occur in health and disease.
It might soon be possible to separate  into different pathogenic andGardnerella 
non-pathogenic species. Many groups are studying compounds that can
disrupt the biofilm which is dominated by  and  .Gardnerella Atopobium vaginae
Several studies in the last decade support the concept of bacterial vaginosis as
a sexually transmitted infection.
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Introduction
Bacterial vaginosis (BV) is the most prevalent cause of abnor-
mal vaginal discharge in women of childbearing age. Those most 
severely affected experience an offensive fishy-smelling discharge 
which recurs frequently, often around the time of menstruation. 
Others may have BV transiently and asymptomatically. It usually 
responds to treatment with antibiotics but can relapse rapidly, and 
reported rates of relapse are more than 50% within 3–6 months. 
There is a need for alternatives to antibiotics and to find a way 
to prevent relapse. Some recent studies imply that it is sexually 
transmitted, with more pathogenic strains of Gardnerella being 
identified. BV is a risk factor for adverse pregnancy outcomes, 
including second-trimester miscarriage, spontaneous preterm 
birth, and post-Caesarean section endometritis. It is also consist-
ently associated with acquisition of sexually transmitted infections 
(STIs), including HIV.
Gardnerella, biofilms and potential treatments
The description of a biofilm on the surface of the vaginal epithe-
lium by Swidsinski and colleagues puts Gardnerella, as the domi-
nant organism, once again at the centre of pathogenesis in BV1. 
The role of Gardnerella as a sexually transmissible organism 
that initiates BV was elegantly discussed by Schwebke and col-
leagues in 20142. Identifying differences in genes and phenotype 
between Gardnerella strains has been the focus of many studies. 
If non-pathological strains of Gardnerella exist, it could explain 
much of the epidemiology. Two strains of Gardnerella—one 
from a woman with BV and one without—were compared in 
20103. Differences were described in some genes and virulence 
factors such as adhesion, cytotoxicity and biofilm-forming capa-
bility. In a larger study, 17 isolates were studied and divided into 
genetically identified clades consistent with subspecies4. Another 
study has confirmed four distinct subgroups of Gardnerella. 
Schellenberg and colleagues used sequencing of the chaperonin-
60 universal target in a diverse group of 112 isolates5. Sialidase 
activity, which is potentially an important mediator of pathogen-
esis through degradation of mucus, was identified in subgroups 
B and C but not A or D. Confusingly, the putative sialidase gene 
was present in some of the sialidase-negative clones. The authors 
conclude that it is likely that Gardnerella will be separated into 
four different species. A further study showed that strains differ 
markedly in their ability to degrade sialoglycans6. It is possible that 
we may eventually be able to differentiate pathogenic from non- 
pathogenic Gardnerella, but it is also possible that there may just 
be a difference of degree of pathogenicity. There is concern about 
increasing levels of metronidazole resistance. I have recently seen 
several cases of clinically metronidazole-refractory BV. Specific 
clades have also been associated with metronidazole resistance. 
Schuyler and colleagues identified intrinsic metronidazole resist-
ance in all of the studied strains from clades 3 and 4, but only 35% 
of clade 1 and 7% of clade 2: clades 1 and 3 were associated with 
BV and 2 and 4 were not7. Interestingly, Alves and colleagues 
compared the ability of Gardnerella and 30 other BV-associated 
bacteria to form a biofilm, adhere to epithelial cells and induce 
cytotoxicity8. Gardnerella was the most potent, once again 
supporting its central role in pathogenesis.
The demonstration of pockets of biofilm persisting after antibi-
otic treatment, and then recovering, has led researchers to study 
how to remove biofilm to achieve cure of BV9. Whether relapse 
is due to this mechanism or to recolonisation from the gut or a 
partner has not been determined. Machado and colleagues exten-
sively reviewed putative agents to potentially be used as adjunc-
tive agents to antibiotics, including octenidine, boric acid, DNAses, 
retrocyclin, subtilosin, ploy-L-lysine, and lauramide arginine ethyl 
ester10. At present, although some of them look promising, clini-
cal evaluation has been limited. Prebiotics in the form of sugars 
used preferentially by lactobacilli and not by Gardnerella or 
Candida seem to be effective in restoring lactobacilli but 
might be needed in the long term to maintain a healthy vaginal 
flora11,12. Amphoteric tenside agents also look effective in vitro, and 
a clinical study of safety and efficacy has started13.
The most recent licensed product for treating BV is dequalinium 
chloride. This is essentially an antiseptic agent. Repeated use, if not 
associated with toxicity, has to be preferable to a repeated course 
of antibiotics for those with frequently recurrent BV. The evi-
dence for its efficacy was reviewed by Mendling and colleagues14. 
This is mostly based on one large multicentre randomized 
controlled trial in which dequalinium chloride was equivalent to 
2% clindamycin cream15. It has some activity against Candida and 
so may be particularly useful for women who recurrently get both 
BV and Candida.
Bacterial vaginosis as a sexually transmitted 
infection
Many studies over the last decade support the concept of BV as 
an STI, including the Australian study, which carefully evaluated 
any sexual activity as well as penile vaginal sex to define a vir-
gin woman16. Epidemiological evidence from several studies has 
established associations between BV and increased numbers of 
sexual partners, inconsistent condom use and young age at sexual 
debut. Zozaya and colleagues reported that sexual exchange of 
BV-associated bacterial taxa between heterosexual couples is 
common17. Molecular sequencing has shown that males carry 
BV-associated bacteria in the sub-preputial space and distal 
urethra18,19, and in one of these, certain bacteria were associated 
with non-gonococcal urethritis18. Additionally, in another study, 
BV-associated bacteria were more prevalent in male partners 
of females with BV than without20, and there was concordance 
of specific BV-associated bacteria and of specific subgroups of 
Gardnerella in heterosexual couples21.
Historically, several studies established that there is a high rate of 
concordance for BV within couples of women who have sex with 
women. More recently, the concept of sexual transmission between 
women was supported by findings that incident BV is associated 
with a new female partner, a female partner with BV and receptive 
oral sex in two prospective cohorts22,23.
However, if BV is sexually transmitted, we do not know whether 
the condition results from transmission of a single agent. Thus, 
Muzny and Schwebke propose a model with Gardnerella as the 
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‘keystone’ organism for the development of BV, with acquisition 
of both Gardnerella and additional anaerobes being sexual24. On 
the other hand, Swidsinski and colleagues described biofilm in the 
urine of male partners of women with BV and described acquisi-
tion of BV in a woman receiving semen including biofilm for 
artificial insemination25,26, implying that it is transmitted as a pol-
ymicrobial consortium. The early studies by Gardner, Dukes and 
colleagues support the latter, as they were more successful in 
transmitting BV with fresh vaginal fluid than a pure growth of 
Gardnerella27.
Gardnerella is found in the gut as well as in the vagina and 
penis. In a thorough review, Kenyon and Osbak discuss the inter-
change of bacteria from a woman’s vagina, oral and rectal micro-
biomes, and those of her partner and the partner’s other sexual 
contacts28. This implies a role for BV-associated organisms in 
the gut to provide a source of recolonisation. Even amongst 
men who have sex with men (MSM), BV-associated organ-
isms are prevalent in the rectum. A study of 107 MSM in Belfast 
found Gardnerella in 83.2% of rectal samples and Mycoplasma 
hominis in 24.3%29. If sexual contact leads to initial colonisation 
with BV, it is remarkably persistent thereafter in many women. 
Perhaps the best evidence that male partners contribute to BV 
was the approximately 50% reduction in BV in women whose 
partners were randomly assigned to circumcision in an HIV pre-
vention study30. Against the STI argument, the rates of persistent/ 
recurrent STIs such as HSV-2 infection increase with age whereas 
BV rates were the same through ages 20–49 in a large study from 
the USA31.
Sex hormones and microbiota
A study of 682 women looked at the correlation between 
contraceptive method and vaginal microbiome32. They found that 
women using combined oral contraception (COC) (odds ratio 
(OR) 0.29) and depot medroxyprogesterone acetate (DMPA) (OR 
0.34) had significantly reduced rates of colonisation with BV- 
associated bacteria compared with those using condoms. Those 
with COC also were more likely to be colonised with H2O2- 
producing lactobacilli (OR 1.94). Women using an intrauterine 
system had greater rates of BV-associated bacteria, but this was 
not statistically significant. This supports the conclusion from 
an earlier study in which hormonal stimulation for in vitro ferti-
lization was associated with a decreased rate of BV33. Combined 
hormonal contraception taken for 3 months continuously is a strat-
egy that needs to be studied for reducing BV by providing both 
increased oestrogen levels and reduced frequency of menstruation. 
This is in keeping with two systematic reviews from 2013 which 
identified the association between use of specific hormonal contra-
ception and reduced risk of BV34,35.
Several studies of the vaginal microbiome have been published 
in recent years. Understanding what is normal vaginal flora 
is clearly relevant to understanding dysbiosis. A large cross- 
sectional study of 396 healthy reproductive-age women used 
culture-independent approaches to classify vaginal bacteria com-
position profiles into five community state types36. Four relatively 
stable lactobacillus-dominated community state types were identi-
fied in 73% of women by using cultivation-independent methods 
based on the analysis of 16S ribosomal RNA (rRNA) gene 
sequences. A fifth corresponded more with dysbiosis and BV. 
However, many of these bacteria produce lactic acid and some of 
these microbiomes were not associated with symptoms37. A full 
discussion of these developments appeared recently in a whole 
journal issue devoted to the vaginal microbiome with a thorough 
editorial written by Crucitti38.
Conclusions
Molecular techniques are giving us new insights into BV. Is there a 
pathogenic type of Gardnerella that is sexually transmitted and can 
be distinguished from benign planktonic strains? Or is BV merely 
sexually associated, such that Gardnerella carriage and exposure 
are almost ubiquitous but something happens with a new sexual 
partner that allows BV to develop? Further studies of the microbi-
ome need to define the apparent normal flora in some women that 
is not dominated by lactobacilli. We might be better able to develop 
probiotic therapies if we can better understand the relationship 
between host and vaginal flora39. We desperately need better ways 
of preventing recurrence that do not involve repeated courses of 
antibiotic. There are several candidate therapies which need to be 
taken into clinical studies.
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